[Case of tuberculous epididymitis caused by intravesical BCG therapy].
Intravesical Bacillus Calmette-Guerin (BCG) therapy is commonly used against superficial urothelial carcinoma, especially carcinoma in situ (CIS). We report a case of tuberculous epididymitis that occurred during a course of intravesical BCG therapy. A 76-year-old man had received intravesical BCG therapy for multiple superficial bladder cancer and CIS in prostatic urethra after transurethral resection of bladder tumor (TUR-Bt). He recognized hard nodules in the left scrotum after 4 times intravesical BCG therapy. Skin fistula in scrotum occurred 5 months later. We performed left orchiectomy with scrotum skin resection. Histological diagnosis was tuberculous epididymitis. Postoperatively, he was administered chemotherapy consisting of isoniazid, refampin and ethambutol.
Koizumi
Takahiro
T
Department of Urology, The University of Tokushima Graduate School Institute of Health Bioscience.
Nakanishi
Ryouiti
R
Taue
Ryuichi
R
Yamaguchi
Kunihisa
K
Nakatuji
Hiroyoshi
H
Kishimoto
Tomoteru
T
Izaki
Hirofumi
H
Oka
Natsuo
N
Takahashi
Masayuki
M
Fukumori
Tomoharu
T
Kanayama
Hiro-omi
HO
D000283:Administration, Intravesical; D000368:Aged; D000995:Antitubercular Agents / Q000008:administration & dosage; D001500:BCG Vaccine / Q000008:administration & dosage* / Q000009:adverse effects*; D002278:Carcinoma in Situ / Q000628:therapy; D015653:Cystectomy; D004822:Epididymis; D006801:Humans; D008297:Male; D009919:Orchiectomy; D014389:Tuberculosis, Male Genital / Q000209:etiology* / Q000473:pathology / Q000628:therapy; D001749:Urinary Bladder Neoplasms / Q000628:therapy
D000995:Antitubercular Agents; D001500:BCG Vaccine